The Science of How Adult Stem Cell Therapy Can Repair Damaged Joints
By: Dr. Noel Peterson
Since 2012, we have been using adult stem cells in an FDA compliant protocol of Regenerative Injection Therapy. Scientists have known for years how combining a person’s own stem cells with PRP (platelet rich plasma) and injecting them directly into the damaged tissue can assist the body to naturally regenerate and repair joint tissue. When combined with proper nutrition, weight loss and exercise, Adult Stem Cell injection has proven to be a viable alternative to major surgery and joint replacement procedures. Studies have shown that AD-MSCs are able to differentiate into several cell types, including cartilage (chondrocytes), heart (cardiomyocytes), vascular endothelial cells, nerve cells, hepatocytes, epithelial cells, and adipocytes, making them an important source for the treatment of a multitude of human diseases. The following article explains some of the science behind why this treatment is so effective and why these Mesenchymal Stem Cells can dramatically improve mobility, decrease pain and serve as a viable alternative to surgery.
Mesenchymal Stem Cells (MSCs) are self-renewing cells and are found in almost every organ and tissue type. MSCs can be isolated from the patient’s own adipose (fat) tissue. Adipose-derived MSCs (AD-MSCs) have many advantages over other sources. Autologous adipose-derived stem cells can be isolated from adipose tissue and lipoaspirates. They can be expanded in culture in large numbers while maintaining pluripotency, or the. Recent studies confirm that among stem cells, AD-MSCs exhibit several advantages for therapeutic use including increased propagation increased the ability to migrate to sites of tissue injury, strong immunosuppressive effects, and the ability to regenerate cartilage, bone, nerve tissue, and heart muscle.
The primary benefits of MSCs are:
Differentiation and regeneration: AD-MSCs have a strong capacity for self-renewal and differentiation into tissues of mesodermal origin (cartilage, connective tissue, muscle, nerves, fat, and bone). This is particularly helpful in osteoarthritic diseases of the large synovial joints, including the hip and knee joints. Previous studies have shown that AD-MSCs are able to differentiate into several cell types, including cartilage (chondrocytes), heart (cardiomyocytes), vascular endothelial cells, nerve cells, hepatocytes, epithelial cells, and adipocytes, making them an important source for the treatment of a multitude of human diseases.
Immune modulation: AD- MSCs have the ability to normalize an over reactive immune system. Research has demonstrated that this is particularly helpful in immune-mediated diseases, including multiple sclerosis, diabetes, and autoimmune arthritis.
Anti-inflammation: AD-MSCs can alter the secretion profile of dendritic cells resulting in increased production of the anti-inflammatory cytokine interleukin (IL)-10 and decreased production of inflammatory interferon-gamma (IFN-r) and IL-12. This is particularly helpful in osteoarthritic diseases of the large synovial joints, including the hip and knee joints. The primary therapeutic effects and use of MSCs is primarily based on their release of trophic and immunomodulatory factors which can inhibit T-cell proliferation (such as TGF-b or IL-10). AD-MSCs can inhibit proliferation of B cells and inhibit IgG secretion.
What it means for you: These benefits can mean effective healing, improved mobility, and decreased pain. Contact us to find out if this treatment is an option for you, and let us help you achieve an active, pain-free lifestyle.
- da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and J Cell Sci 2006;119(part 11):2204–2213.
- A. Zuk, M. Zhu, H. Mizuno et al., “Multilineage cells from human adipose tissue: implications for cell-based therapies,” Tissue Engineering, vol. 7, no. 2, pp. 211–228, 2001
- Noelle Knight et al. Mesenchymal Stem Cells in Bone Regeneration. Advance in Wound Care. 2013; 6,2
- Xie QP, Huang H, Xu B et Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon micro- environmental manipulation in vitro. Differentiation 2009;77:483–491.
- Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–
- Abdi R, Fiorina P, Adra CN et al. Immunomodulation by mesenchymal stem cells: A potential therapeutic strategy for type 1 Diabetes 2008;57:1759–1767.
- Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499–3506.
- Volarevic V, Al-Qahtani A, Arsenijevic N et al. Interleukin-1 recep- tor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 2010;43:255–263.
- Zdravkovic N, Shahin A, Arsenijevic N et Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Mol Immunol 2009;47:28–36.
- Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;1